A #Stanford_Medicine neurologist explains why a trio of closely related drugs all aimed at treating #Alzheimers_disease -- while so promising in theory --don’t appear to be helping patients much if at all. #plaque_attack_fail
https://t.co/O4Bs2k78AJ
Thank you @brucegoldman for highlighting and nicely summarizing our recent commentary on the limitations of recent anti-amyloid trials.
https://t.co/sVfxJ3UbQm
If you’re at #ADPD2024 and curious about how Amantadine works in PD, please stop by either today or tomorrow at poster 454. Great meeting so far in Lisbon!
Another month of wards in the books! Feeling grateful to have gotten to work with the best senior (@EmilyLChu) best co-intern (@XC_Cortez) and best med student (@MedMusicMel) @StanfordMedRes
Great piece in @journal_ad from @leonardinosaur@joe__winer and Michael Greicius from Stanford on functional unblinding, amyloid removal as a surrogate, and data transparency.
Substantial Doubt Remains about the Efficacy of Anti-Amyloid Antibodies
https://t.co/QCuhiFwbVW
S/p ten (10) day stretch to cap off another month on the @StanfordMedRes wards. Tough to be away from friends/fam over the holidays, but ‘twas nice working with and getting to know my future @Stanford_Neuro co-res Akshara!
My newest project with @PaLab_UCSD exploring the role of cerebrovascular reactivity in developing mild cognitive impairment is now out in @alzdemjournals!🧠https://t.co/H5RBSGGhfu
An interesting and relevant piece worth reading, by my postdoc mentor Mike Greicius: "Substantial Doubt Remains about the Efficacy of Anti-Amyloid Antibodies"
https://t.co/YNzmdJqKHB
Is it possible to cure #AlzheimersDisease? The press has been so enthusiastic about anti-amyloid antibodies, but are they really improving patients? In this @arxiv lead by my P.I. Michael Greicius, some doubts still remain. 👉 https://t.co/EZ50Yw9p7R @StanfordMed@Stanford_Neuro
With #CTAD23 happening, it is an exciting week for the AD field. To contribute to the discussion, we (I, @joe__winer, and Mike Greicius) wanted to highlight three observations regarding recent anti-amyloid clinical trials:
https://t.co/2yNv4UZ9PJ
@alleolabs@VahanAslanyan Not sure! Although I think there is a process for requesting data from ADCS trials that might be helpful https://t.co/ySwNXDwcwG
Sad that I can’t be in Amsterdam for #AAIC23 but excited to share our work as a virtual poster for the conference. This project involved a post-hoc analysis of the EXERT trial, looking at the association between amount of exercise completed and regional brain atrophy.
@alleolabs@VahanAslanyan Sorry for the delay in replying here. For our analyses, we averaged across L and R hippocampus, b/c I did not feel there was strong aprior reason that exercise would associate with just the L or just the R side. Although we can certainly look into it.
Looking forward to digging into these associations further. Feel free to reach out if you have any questions or want a higher resolution version of the poster.